NASDAQ: URGN - UroGen Pharma Ltd.

Rentabilität für sechs Monate: -9.84%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan UroGen Pharma Ltd.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.

weitere details
It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2017-05-04
ISIN IL0011407140
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.urogen.com
Цена ао 11.52
Preisänderung pro Tag: 0% (11.45)
Preisänderung pro Woche: -5.61% (12.13)
Preisänderung pro Monat: +22.33% (9.36)
Preisänderung über 3 Monate: +6.41% (10.76)
Preisänderung über sechs Monate: -9.84% (12.7)
Preisänderung pro Jahr: -23.67% (15)
Preisänderung über 3 Jahre: +31.76% (8.69)
Preisänderung über 5 Jahre: -59.12% (28.01)
Preisänderung seit Jahresbeginn: +8.84% (10.52)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 4.99 3
P/BV -51.24 0
P/E 0 0
EV/EBITDA -4.16 0
Gesamt: 4.13

Effizienz

Name Bedeutung Grad
ROA, % -54.68 0
ROE, % 342.83 10
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -1.27 10
Gesamt: 7.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 666.08 10
Rentabilität Ebitda, % -23.61 0
Rentabilität EPS, % -49.85 0
Gesamt: 2
Weitere Details

Institutionen Volumen Aktie, %
Great Point Partners LLC 2620545 8.49
Menora Mivtachim Holdings Ltd. 2303031 7.46
RA Capital Management, L.P. 1483697 4.81
Blackrock Inc. 1197647 3.88
Credit Suisse Ag/ 1060000 3.43
Harel Insurance Investments & Financial Services Ltd. 870194 2.82
RTW Investments LP 857464 2.78
Migdal Insurance & Financial Holdings Ltd. 648302 2.1
SILVERARC CAPITAL MANAGEMENT, LLC 508883 1.65
Wildcat Capital Management, LLC 495606 1.61

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
ARK Israel Innovative Technology ETF 1.67779 24.64 1.21688
Amplify BlueStar Israel Technology ETF 0.57399 20.42 0.47569
iShares Micro-Cap ETF 0.12986 17.09 1.54048
Future Tech ETF 0.05533 426.34 0.8416
Principal Healthcare Innovators ETF 0.05533 618.5 0.8416
Invesco Nasdaq Biotechnology ETF 0.04838 28.58 0.8565
ProShares Ultra Nasdaq Biotechnology 0.03147 51.7 0.85651
SPDR S&P International Small Cap ETF 0.03065 8.94 3.10348
Vanguard Russell 2000 Growth ETF 0.03 23.05 0.60264
iShares Russell 2000 Growth ETF 0.02916 38.04 0.6026
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.02471 31.36 1.41955
Vanguard Russell 2000 ETF 0.02 17.16 1.48801
ProShares UltraPro Russell2000 0.01005 89.82 1.47873
SPDR Portfolio Developed World ex-US ETF 0.00776 5.29 3.28401
Fidelity MSCI Health Care Index ETF 0.00575 3 1.46057
ProShares Hedge Replication ETF 0.00273 5.92 1.47892
iShares Russell 3000 ETF 0.00087 24.83 1.43482
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.1581.471.36



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Ms. Elizabeth A. Barrett President, CEO & Director 1.12M 1962 (63 Jahr)
Mr. Dong Kim Chief Financial Officer 546.68k 1977 (48 Jahre)
Mr. Jason Drew Smith General Counsel, Chief Compliance Officer & Corporate Secretary 717.58k 1972 (53 Jahr)
Vincent I. Perrone Senior Director of Investor Relations N/A
Mr. Bryon Wornson Executive Vice President of Talent, Advocacy & Communications N/A
Dr. Mark P. Schoenberg M.D. Chief Medical Officer 579.5k 1958 (67 Jahre)
Mr. James Ottinger R.ph. Executive Vice President of Regulatory Affairs & Quality N/A
Dr. Marina Konorty Ph.D. Executive Vice President of Research & Development and Technical Operations
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. Chief Business Officer 1965 (60 Jahre)
Mr. Michael J. Louie M.D., M.P.H., M.Sc. Senior Vice President of Medical Affairs & Clinical Development

Adresse: United States, Princeton. NJ, 400 Alexander Park - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.urogen.com